SVB Wealth LLC Buys New Holdings in Akoya Biosciences, Inc. (NASDAQ:AKYA)

SVB Wealth LLC acquired a new position in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 515,398 shares of the company's stock, valued at approximately $1,180,000. SVB Wealth LLC owned approximately 1.04% of Akoya Biosciences as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp boosted its stake in Akoya Biosciences by 4.2% in the 3rd quarter. State Street Corp now owns 453,296 shares of the company's stock worth $1,233,000 after purchasing an additional 18,361 shares during the period. GSA Capital Partners LLP boosted its position in shares of Akoya Biosciences by 87.4% during the third quarter. GSA Capital Partners LLP now owns 310,669 shares of the company's stock worth $845,000 after buying an additional 144,903 shares during the period. Barclays PLC grew its holdings in shares of Akoya Biosciences by 320.9% during the third quarter. Barclays PLC now owns 39,472 shares of the company's stock worth $107,000 after buying an additional 30,095 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Akoya Biosciences in the 4th quarter valued at approximately $28,000. 79.42% of the stock is currently owned by institutional investors and hedge funds.

Akoya Biosciences Stock Down 2.8 %

Shares of Akoya Biosciences stock traded down $0.05 on Thursday, reaching $1.56. 152,882 shares of the company were exchanged, compared to its average volume of 340,322. Akoya Biosciences, Inc. has a one year low of $1.43 and a one year high of $5.41. The company has a current ratio of 2.75, a quick ratio of 1.85 and a debt-to-equity ratio of 5.62. The company has a 50-day moving average of $2.46 and a 200 day moving average of $2.58. The company has a market capitalization of $77.09 million, a price-to-earnings ratio of -1.32 and a beta of 1.23.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Craig Hallum downgraded Akoya Biosciences from a "buy" rating to a "hold" rating and reduced their price target for the stock from $7.00 to $5.00 in a research report on Friday, November 15th. Canaccord Genuity Group cut shares of Akoya Biosciences from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $3.00 price target (down from $4.00) on shares of Akoya Biosciences in a research note on Tuesday, November 19th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Akoya Biosciences has an average rating of "Hold" and a consensus target price of $5.08.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.